Related references
Note: Only part of the references are listed.Increase of CSF tyrosine and impaired serotonin turnover in tyrosinemia type I
Eva Thimm et al.
MOLECULAR GENETICS AND METABOLISM (2011)
Liquid chromatography tandem mass spectrometry method for the quantitation of NTBC (2-(nitro-4-trifluoromethylbenzoyl)1,3-cyclohexanedione) in plasma of tyrosinemia type 1 patients
Diran Herebian et al.
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES (2009)
Tyrosine promotes oxidative stress in cerebral cortex of young rats
Angela M. Sgaravatti et al.
INTERNATIONAL JOURNAL OF DEVELOPMENTAL NEUROSCIENCE (2008)
NTBC treatment in tyrosinaemia type I: Long-term outcome in French patients
A. Masurel-Paulet et al.
JOURNAL OF INHERITED METABOLIC DISEASE (2008)
Brain magnetic resonance imaging in tyrosinemia
RN Sener
ACTA RADIOLOGICA (2005)
Tyrosinemia - Computed tomography, magnetic resonance imaging, diffusion magnetic resonance imaging, and proton spectroscopy findings in the brain
RN Sener
JOURNAL OF COMPUTER ASSISTED TOMOGRAPHY (2005)
Long-term therapy with NTBC and tyrosine-restricted diet in a murine model of hereditary tyrosinemia type I
M Al-Dhalimy et al.
MOLECULAR GENETICS AND METABOLISM (2002)
Outcome of tyrosinaemia type III
CJ Ellaway et al.
JOURNAL OF INHERITED METABOLIC DISEASE (2001)
Tyrosinemia type II: Nine cases of ocular signs and symptoms
MS Macsai et al.
AMERICAN JOURNAL OF OPHTHALMOLOGY (2001)
Pharmacokinetics and pharmacodynamics of NTBC (2-(2-nitro-4-fluoromethylbenzoyl)-1,3-cyclohexanedione) and mesotrione, inhibitors of 4-hydroxyphenyl pyruvate dioxygenase (HPPD) following a single dose to healthy male volunteers
MG Hall et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2001)
Share Paper
